肝细胞癌多模态图谱揭示趋同进化路径及「坏苹果」效应对临床轨迹的影响
该前瞻性队列通过亚太肝细胞癌试验组(NCT03267641)纳入123例初治患者,采集逾600份全基因组与转录组样本。多区域采样揭示七条由早期驱动突变、晚期拷贝数变异和病毒整合调控的趋同遗传进化路径,可分层术后临床轨迹;肿瘤内最侵袭性细胞成分而非整体转录组异质性水平最能预测预后,称为「坏苹果」效应。
要点
- 七条趋同遗传进化路径由早期驱动突变、晚期拷贝数变异和病毒整合调控,可分层患者术后临床轨迹。
- 进化路径塑造分子谱并导致不同转录组亚型,部分肿瘤内共存多种转录组亚型。
- 患者预后由最侵袭性细胞成分而非整体转录组肿瘤内异质性水平最佳预测,即「坏苹果」效应。
核心结论
- 研究构建了肝细胞癌进化历史的全面图谱,为理解肿瘤异质性与临床轨迹提供丰富的多组学资源。
- 不同进化路径与「坏苹果」效应影响疾病进展,最侵袭性肿瘤成分决定疾病进展。
- 同一肿瘤内多种亚型共存提示需重新评估依赖单一样本代表整个肿瘤的效用,并提示需要临床分子影像。
研究设计与样本
- 通过亚太肝细胞癌试验组(NCT03267641)开展前瞻性队列研究,纳入123例初治肝细胞癌患者。
- 采集逾600份全基因组与转录组样本,采用多区域采样方法。
- 临床试验注册号NCT03267641为观察性队列。
主要发现
- 揭示七条由早期驱动突变、晚期拷贝数变异和病毒整合调控的趋同遗传进化路径,可分层患者术后临床轨迹。
- 进化路径塑造分子谱,导致不同转录组亚型,部分肿瘤内共存多种转录组亚型。
- 患者预后由最侵袭性细胞成分而非整体转录组肿瘤内异质性水平最佳预测,称为「坏苹果」效应。
- 早期与晚期肿瘤进化特征对预测患者生存具有显著且互补的预后价值。
临床怎么用
- 作者指出这些发现有助于提高术后预后准确性,并为根据特定肿瘤进化与转录组谱制定个体化治疗策略铺路。
- 作者认为同一肿瘤内多种亚型共存提示需重新评估依赖单一样本代表整个肿瘤的效用,并提示需要临床分子影像。
- 作者强调将肿瘤进化动力学与多组学生物标志物整合入治疗决策的重要性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a highly fatal cancer characterized by high intra-tumor heterogeneity (ITH). A panoramic understanding of its tumor evolution, in relation to its clinical trajectory, may provide novel prognostic and treatment strategies. METHODS: Through the Asia-Pacific Hepatocellular Carcinoma trials group (NCT03267641), we recruited one of the largest prospective cohorts of patients with HCC, with over 600 whole genome and transcriptome samples from 123 treatment-naïve patients. RESULTS: Using a multi-region sampling approach, we revealed seven convergent genetic evolutionary paths governed by the early driver mutations, late copy number variations and viral integrations, which stratify patient clinical trajectories after surgical resection. Furthermore, such evolutionary paths shaped the molecular profiles, leading to distinct transcriptomic subtypes. Most significantly, although we found the coexistence of multiple transcriptomic subtypes within certain tumors, patient prognosis was best predicted by the most aggressive cell fraction of the tumor, rather than by overall degree of transcriptomic ITH level - a phenomenon we termed the 'bad apple' effect. Finally, we found that characteristics throughout early and late tumor evolution provide significant and complementary prognostic power in predicting patient survival. CONCLUSIONS: Taken together, our study generated a comprehensive landscape of evolutionary history for HCC and provides a rich multi-omics resource for understanding tumor heterogeneity and clinical trajectories. IMPACT AND IMPLICATIONS: This prospective study, utilizing comprehensive multi-sector, multi-omics sequencing and clinical data from surgically resected hepatocellular carcinoma (HCC), reveals critical insights into the role of tumor evolution and intra-tumor heterogeneity (ITH) in determining the prognosis of HCC. These findings are invaluable for oncology researchers and clinicians, as they underscore the influence of distinct evolutionary paths and the 'bad apple' effect, where the most aggressive tumor fraction dictates disease progression. These insights not only enhance prognostic accuracy post-surgical resection but also pave the way for personalized treatment strategies tailored to specific tumor evolutionary and transcriptomic profiles. The coexistence of multiple subtypes within the same tumor prompts a re-appraisal of the utilities of depending on single samples to represent the entire tumor and suggests the need for clinical molecular imaging. This research thus marks a significant step forward in the clinical understanding and management of HCC, underscoring the importance of integrating tumor evolutionary dynamics and multi-omics biomarkers into therapeutic decision-making. CLINICAL TRIAL NUMBER: NCT03267641 (Observational cohort).
引用
- Chen J, Kaya NA, Zhang Y, et al. A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and 'bad apple' effect on clinical trajectory. J Hepatol. 2024. PMID: 38782118. doi:10.1016/j.jhep.2024.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。